Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FCRL5 CAR-T clone 942
- Development stage
- Preclinical
- Lead developer
- Alloy Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FCRL5 CAR-T clone 942 is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target Fc receptor-like 5 (FCRL5), a protein specifically expressed on the surface of malignant plasma cells in multiple myeloma. The therapy utilizes a humanized single-chain variable fragment (scFv) derived from clone 942, which specifically binds to the membrane-proximal D9 domain of the FCRL5 extracellular region. This binding site is strategically chosen to enhance the formation of the immunological synapse. The CAR construct incorporates a 4-1BB costimulatory domain and a CD3z signaling domain to drive T-cell activation and persistence. Preclinical evaluations in mouse xenograft models have demonstrated that clone 942 significantly reduces tumor burden and extends survival, supporting its potential as a therapeutic candidate for relapsed or refractory multiple myeloma.
- Other names
- FCRL5 CAR-T (clone 942)
02
Targets
FCRL5 (Fc receptor-like protein 5)
Beyond the preview
Go deeper on FCRL5 CAR-T clone 942.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FCRL5 CAR-T clone 942.